Abstract

 By January 7, 2020, Chinese scientists had isolated a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV), from these patients with virus-infected pneumonia, which was later designated coronavirus disease 2019 (COVID-19) in February, 2020, by WHO. Severe SARS-CoV-2-associated disease COVID-19 was declared a pandemic by the WHO in March 2020 and is characterized by cytokine storm, acute respiratory distress syndrome, and in some cases by systemic inflammation related pathology. A deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages. Monitoring of biochemical and hematological parameters is essential and can assist in the identification of patients who will need care in the ICU and could discriminate survivors and non-survivors too. Generally, it’s imperative to regulate innate and adaptive immunity for better control of immune response consequence and for development of drug or vaccine. Biochemical and hematological parameters could serve for diagnosis, prognosis or monitoring especially for hospitalized patients of the Covid19 infection. Finally, the contribution of asymptomatic cases in the transmission deserve further studies to examine the extent of occurrence and the role in transmission, and also the immunity status of those individuals should be assessed very well.

Keywords: Covid19; Immunological; Hematological; Biochemical

References

1. Rabi FA., et al. “SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far”. Pathogens 9 (2020): 231.
2. Novel coronavirus (2019-nCoV) situation report - 11 (website). WHO (2020).
3. Lee A. “Wuhan novel coronavirus (COVID-19): why global control is challenging?” Public Health 179 (2020): A1-A2.
4. Zhou F., et al. “Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 395 (2020): 1054-1062.
5. Zhong J., et al. “The immunology of COVID-19: is immune modulation an option for treatment?” Lancet Rheumatology (2020).
6. Nishiura H., et al. “Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)”. International Journal of Infectious Diseases 94 (2020): 154-155C.
7. Al-Tawfiq JA. “Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)”. Travel Medicine and Infectious Disease 15 (2020).
8. Vabret N., et al. “Immunology of COVID-19: Current State of the Science, Review”. Immunity 52 (2020): 910-941.
9. Li G., et al. “Coronavirus infections and immune responses, review”. Journal f Medical Virology (2020): 1-9.
10. Wang R., et al. “Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China”. International Journal of Infectious Diseases 95 (2020): 421-428.
11. Catanzaro M., et al. “Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2, Review Article”. Signal Transduction and Targeted Therapy 5 (2020): 84.
12. Pence BD. “Severe COVID-19 and aging: are monocytes the key? Review Article”. GeroScience (2020).
13. Zhang X., et al. “Viral and host factors related to the clinic outcome of COVID-19”. Nature (2020).
14. Long Q-X., et al. “Infections Clinical and immunological assessment of asymptomatic SARS-CoV-2”. Nature Medicine (2020).
15. Zhu Z., et al. “Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019”. International Journal of Infectious Diseases 95 (2020): 332-339.
16. Xiang J., et al. “Potential biochemical markers to identify severe cases among COVID-19 patients”. MedRxiv (2020).
17. Duarte FB., et al. “Hematological changes in Covid-19 infections”. Revista da Associação Médica Brasileira 2 (2020): 99-992.
18. Chen R., et al. “Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China”. The Journal of Allergy and Clinical Immunology (2020): 1-12.
19. Henry BM. “Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis”. Clinical Chemistry and Laboratory Medicine (CCLM) Published online:10 Apr 2020 (2020).
20. Dinga X., et al. “Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019”. Clinical Chemistry and Laboratory Medicine (2020): 1-7.
21. Velavan TP and Meyer CG. “Mild versus severe COVID-19: Laboratory markers”. International Journal of Infectious Diseases 95 (2020): 304-307.
22. Lavezzo E., et al. “Suppression of COVID-19 outbreak in the municipality of VO, Italy”. MedRxiv (2020).
23. Zietz M and Tatonetti NP. “Testing the association between blood type and COVID-19 infection, intubation, and death”. MedRxiv (2020).
24. Zhao J., et al. “Relationship between the ABO Blood Group and the COVID-19 Susceptibility”. MedRxiv (2020).

Citation

Citation: Fekadu Urgessa. “Biochemical, Hematological and Immunological Parameters among Covid19 Infected Patients - Short Review". Acta Scientific Clinical Case Reports 1.10 (2020): 04-08.

Copyright

Copyright: © 2020 Fekadu Urgessa. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.